ClinVar Miner

Submissions for variant NM_000030.3(AGXT):c.116_117dup (p.Ala40fs)

gnomAD frequency: 0.00001  dbSNP: rs180177166
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Counsyl RCV000186382 SCV000486452 likely pathogenic Primary hyperoxaluria, type I 2016-06-03 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001175458 SCV001339029 likely pathogenic Primary hyperoxaluria 2022-05-10 criteria provided, single submitter clinical testing Variant summary: AGXT c.116_117dupCA (p.Ala40GlnfsX7) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 4e-05 in 247578 control chromosomes (gnomAD). This frequency is not higher than the estimated maximum expected for a pathogenic variant in AGXT causing Primary Hyperoxaluria Type 1 (0.0024), allowing no conclusion about variant significance.c.116_117dupCA has been reported in the literature in individuals affected with Primary Hyperoxaluria Type 1 (Coulter-Mackie_2005, Williams_2007, Williams_2015). These data indicate that the variant may be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two ClinVar submitters have assessed the variant since 2014: one classified the variant as likely pathogenic and one as pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic.
Invitae RCV001857594 SCV002245288 pathogenic not provided 2023-09-01 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Ala40Glnfs*7) in the AGXT gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in AGXT are known to be pathogenic (PMID: 19479957). This variant is present in population databases (rs762245382, gnomAD 0.008%). This premature translational stop signal has been observed in individual(s) with clinical features of primary hyperoxaluria (PMID: 15963748). This variant is also known as 117_118insCA. ClinVar contains an entry for this variant (Variation ID: 204175). For these reasons, this variant has been classified as Pathogenic.
Baylor Genetics RCV000186382 SCV004192739 pathogenic Primary hyperoxaluria, type I 2023-03-23 criteria provided, single submitter clinical testing
Mayo Clinic Laboratories, Mayo Clinic RCV001857594 SCV004226745 likely pathogenic not provided 2023-03-03 criteria provided, single submitter clinical testing PS4_moderate, PVS1
Clinical Biochemistry Laboratory, Health Services Laboratory RCV000186382 SCV000239732 pathogenic Primary hyperoxaluria, type I 2014-11-27 no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.